MindMed Archives

Psychedelics News

MindMed

Industry

25 Aug 2022

MindMed Doses First Patient in Phase 2b Trial

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder...

By Microdose NewsDesk

Industry

18 Aug 2022

MindMed’s Path Through the Clinical Trial Process

On January 25th, 2022 the Food and Drug Administration (FDA) cleared MindMed’s MM-120 Investigational New Drug (IND), an LSD-based drug directed at treating generalized anxiety disorder, the first of its...

By Robert Toland

Breaking News, Finance

18 Aug 2022

Breaking News: MindMed Stock Jumps Over 60%

Investors woke up this morning to a serious shroom stock buzz....

By Jason Najum

Breaking News, Industry

12 Aug 2022

Breaking News: MindMed Halts 18-MC (MM-110) Opioid Withdrawal Program

Yesterday MindMed released its financial results and held its earnings call, announcing the shelving of its 18-MC (MM-110) program for opioid withdrawal....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

22 Jul 2022

A Deeper Look at MindMed’s Corporate Update

MindMed has released its Corporate Overview....

By Jason Najum

Science

14 Jul 2022

Science Feature: Next-Generation Psychedelics

Next-generation psychedelics are compounds whose structure derives or is built upon classical psychedelics like DMT, LSD and psilocybin — yet changed by inserting modifications to reduce possible adverse effects....

By Elisabetta Fato

Industry

27 Jun 2022

Compass Wins Patent Case; MindMed Granted Patent For MDMA and LSD

Compass Pathways and MindMed get patent wins in controversial patent claims...

By Jason Najum

Industry

3 Jun 2022

The Top Clinical Trials in 2022

2022 is expected to be a pivotal year, with the psychedelic industry attempting to solidify itself as a commercially viable endeavor....

By Jason Najum

Industry

19 May 2022

MindMed Releases Phase 1 Trial Results For Opioid Addiction

MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal...

By Jason Najum

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result